-$0.62 EPS Expected for Mirati Therapeutics, Inc. (MRTX) This Quarter
Analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to post ($0.62) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Mirati Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.75). Mirati Therapeutics posted earnings per share of ($0.99) during the same quarter last year, which indicates a positive year-over-year growth rate of 37.4%. The business is scheduled to announce its next earnings results on Thursday, March 8th.
On average, analysts expect that Mirati Therapeutics will report full-year earnings of ($2.73) per share for the current financial year, with EPS estimates ranging from ($2.88) to ($2.54). For the next financial year, analysts forecast that the company will post earnings of ($2.50) per share, with EPS estimates ranging from ($3.53) to ($1.86). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Mirati Therapeutics.
Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16.
In other Mirati Therapeutics news, SVP Jamie Christensen sold 7,499 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total value of $104,986.00. Following the sale, the senior vice president now directly owns 10,169 shares in the company, valued at $142,366. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Venbio Select Advisor Llc bought 650,000 shares of the stock in a transaction on Thursday, November 16th. The stock was purchased at an average price of $13.00 per share, for a total transaction of $8,450,000.00. The disclosure for this purchase can be found here. Insiders own 5.10% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of MRTX. Susquehanna International Group LLP raised its stake in shares of Mirati Therapeutics by 46.5% during the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 16,030 shares during the period. PDT Partners LLC bought a new stake in shares of Mirati Therapeutics during the 2nd quarter valued at $200,000. Citadel Advisors LLC bought a new stake in shares of Mirati Therapeutics during the 3rd quarter valued at $268,000. Goldman Sachs Group Inc. raised its stake in shares of Mirati Therapeutics by 845.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 87,858 shares during the period. Finally, OxFORD Asset Management LLP bought a new stake in shares of Mirati Therapeutics during the 3rd quarter valued at $365,000. Hedge funds and other institutional investors own 64.68% of the company’s stock.
Shares of Mirati Therapeutics (NASDAQ:MRTX) traded down $0.40 during trading on Friday, reaching $18.70. The company’s stock had a trading volume of 234,793 shares, compared to its average volume of 380,529. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.70. The firm has a market capitalization of $515.58, a PE ratio of -6.01 and a beta of 1.79.
ILLEGAL ACTIVITY WARNING: “-$0.62 EPS Expected for Mirati Therapeutics, Inc. (MRTX) This Quarter” was first published by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.mareainformativa.com/2018/01/29/0-62-eps-expected-for-mirati-therapeutics-inc-mrtx-this-quarter-updated-updated-updated.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.